Xenon Pharmaceuticals (XENE) Return on Sales (2013 - 2025)

Xenon Pharmaceuticals (XENE) has 11 years of Return on Sales data on file, last reported at 0.0% in Q4 2025.

• Return on Sales for Q4 2025 came in at 0.0%, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was 0.0% (changed N/A YoY), and the FY2025 annual result was 0.0%, changed N/A from the prior year.
• Return on Sales advanced to 0.0% in Q4 2025 per XENE's latest filing, from 0.42% in the prior quarter.
• Over five years, Return on Sales peaked at 0.0% in Q4 2025 and troughed at 14.46% in Q2 2024.
• A 4-year average of 1.56% and a median of 0.11% in 2022 frame the typical range for Return on Sales.
• The sharpest annual moves came in 2022 and 2025: Return on Sales tumbled 278 bps in 2022, then soared 1408 bps in 2025.
• A 4-year view of Return on Sales shows it stood at 0.07% in 2021, then slumped by 88 bps to 0.13% in 2022, then slumped by 11132 bps to 14.46% in 2024, then surged by 100 bps to 0.0% in 2025.
• Business Quant data shows XENE's Return on Sales at 0.0% in Q4 2025, 0.42% in Q3 2025, and 0.38% in Q2 2025.